Effect of phytocomposition on dyslipidemia in patients with SARS-CoV-2 infection at the health resort stage of treatment

Background. Cardiovascular events are the main threat in the post-COVID period, and  their risk is  increased in  patients who have had a  new coronavirus infection (SARS-CoV-2). In this regard, the  direction of  studying the  correction of  already well-studied modifiable risk factors is of particular relevance. One of such factors is certainly dyslipidemia.

The aim. To study the level of blood lipids in patients after new coronavirus infection and the possibility of its correction during rehabilitation in sanatorium conditions with the additional use of the phytotherapy.

Materials and methods. The study included 50 people who, according to their medical history, had suffered from SARS-CoV-2 infection and were admitted to sanatorium treatment. All patients underwent a course of rehabilitation measures lasting 20 days. Before and after the course of rehabilitation, patients underwent laboratory analysis, which included the main biochemical parameters, including total cholesterol, lowdensity lipoproteins, high-density lipoproteins and triglycerides. The respondents were divided into two groups – experimental (group 1; n = 21) and control (group 2; n = 29). Patients from group 1 received tea from a phytocomposition in addition to standard measures.

Results. In  the  group receiving tea based on  herbal phytocomposition, there was a statistically significant decrease in total cholesterol from 6.91 ± 1.75 to  5.9  ±  1.64  mmol/l (p  =  0.04) and  low-density lipoproteins from 4.68  ±  1.65 to  3.78  ±  1.28  mmol/l (p  =  0.038). No  changes were detected in  these indicators, as well as in the level of triglycerides in group 2.

Conclusion. The  use of  the  phytocomposition presented in  the  study during the course allowed a statistically significant reduction in low-density lipoproteins levels in the blood of post-Covid patients by more than 0.9 ± 1.85 mmol/l. The use of phytopreparations in order to reduce the risk of cardiovascular events in patients who have undergone new coronavirus infection is a promising area that requires more detailed in-depth studies.

1. COVID-19 coronavirus pandemic worldometer. URL: https://www.worldometers.info/coronavirus [date of access: 18.04.2024].

2. Chuang HJ, Lin CW, Hsiao MY, Wang TG, Liang HW. Long COVID and rehabilitation. J Formos Med Assoc. 2024; 123(1): S61- S69. doi: 10.1016/j.jfma.2023.03.022

3. Mitrani RD, Dabas N, Alfadhli J, Lowery MH, Best TM, Hare JM, et al. Long-term cardiac surveillance and outcomes of COVID-19 patients. Trends Cardiovasc Med. 2022; 32(8): 465-475. doi: 10.1016/j.tcm.2022.06.003

4. Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023; 15(2): 508. doi: 10.3390/v15020508

5. Chilosi M, Doglioni C, Ravaglia C, Piciucchi S, Dubini A, Stefanizzi L, et al. COVID-19. Biology, pathophysiology, and immunology: A pathologist view. Pathologica. 2023; 115(5): 248-256. doi: 10.32074/1591-951X-954

6. Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022; 43(4): 611-653. doi: 10.1210/endrev/bnab037

7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455

8. Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021; 10: e73873. doi: 10.7554/eLife.73873

9. Grewal T, Nguyen MKL, Buechler C. Cholesterol and COVID19-therapeutic opportunities at the host/virus interface during cell entry. Life Sci Alliance. 2024; 7(5): e202302453. doi: 10.26508/lsa.202302453

10. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022; 612(7941): 758-763. doi: 10.1038/s41586-022-05542-y

11. Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022; 43(34): 3198-3208. doi: 10.1093/eurheartj/ehab841

12. Attardo S, Musumeci O, Velardo D, Toscano A. Statins neuromuscular adverse effects. Int J Mol Sci. 2022; 23(15): 8364. doi: 10.3390/ijms23158364

13. Ji X, Shi S, Liu B, Shan M, Tang D, Zhang W, et al. Bioactive compounds from herbal medicines to manage dyslipidemia. Biomed Pharmacother. 2019; 118: 109338. doi: 10.1016/j.biopha.2019.109338

14. Olennikov DN, Kashchenko NI. Marigold metabolites: Diversity and separation methods of calendula genus phytochemicals from 1891 to 2022. Molecules. 2022; 27(23): 8626. doi: 10.3390/molecules27238626

15. Bonaterra GA, Bronischewski K, Hunold P, Schwarzbach H, Heinrich EU, Fink C, et al. Anti-inflammatory and anti-oxidative effects of Phytohustil® and root extract of Althaea officinalis L. on macrophages in vitro. Front Pharmacol. 2020; 11: 290. doi: 10.3389/fphar.2020.00290

16. Zhakipbekov K, Turgumbayeva A, Issayeva R, Kipchakbayeva A, Kadyrbayeva G, Tleubayeva M, et al. Antimicrobial and other biomedical properties of extracts from Plantago major, Plantaginaceae. Pharmaceuticals (Basel). 2023; 16(8): 1092. doi: 10.3390/ph16081092

17. Burlou-Nagy C, Bănică F, Jurca T, Vicaș LG, Marian E, Muresan ME, et al. Echinacea purpurea (L.) Moench: Biological and pharmacological properties. A Review. Plants (Basel). 2022; 11(9): 1244. doi: 10.3390/plants11091244

18. Sah A, Naseef PP, Kuruniyan MS, Jain GK, Zakir F, Aggarwal G. A comprehensive study of therapeutic applications of chamomile. Pharmaceuticals (Basel). 2022; 15(10): 1284. doi: 10.3390/ph15101284

19. Budantsev AL, Prikhodko VA, Varganova IV, Okovitiy SV. Biological activity of Hypericum perforatum L. (Hypericaceae): A review. Pharmacy & Pharmacology. 2021; 9(1): 17-31. (In Russ.). doi: 10.19163/2307-9266-2021-9-1-17-31

20. Sharifi-Rad J, Quispe C, Herrera-Bravo J, Belén LH, Kaur R, Kregiel D, et al. Glycyrrhiza genus: Enlightening phytochemical components for pharmacological and health-promoting abilities. Oxid Med Cell Longev. 2021; 2021: 7571132. doi: 10.1155/2021/7571132

21. Das B, Rabalais J, Kozan P, Lu T, Durali N, Okamoto K, et al. The effect of a fennel seed extract on the STAT signaling and intestinal barrier function. PLoS One. 2022; 17(7): e0271045. doi: 10.1371/journal.pone.0271045

22. Adel Mehraban MS, Tabatabaei-Malazy O, Rahimi R, Daniali M, Khashayar P, Larijani B. Targeting dyslipidemia by herbal medicines: A systematic review of meta-analyses. J Ethnopharmacol. 2021; 280: 114407. doi: 10.1016/j.jep.2021.114407

23. Gyawali D, Vohra R, Orme-Johnson D, Ramaratnam S, Schneider RH. A systematic review and meta-analysis of ayurvedic herbal preparations for hypercholesterolemia. Medicina (Kaunas). 2021; 57(6): 546. doi: 10.3390/medicina57060546

24. Ba Tuyen P, Huyen TT, Hang DTT, Thi Van Anh P. A novel herbal medicine for dyslipidemia: Assessments in experimental models. Evid Based Complement Alternat Med. 2021; 2021: 5529744. doi: 10.1155/2021/5529744

25. Qin Y, Xia M, Ma J, Hao Y, Liu J, Mou H, et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr. 2009; 90(3): 485-492. doi: 10.3945/ajcn.2009.27814

26. Ren K, Jiang T, Zhao GJ. Quercetin induces the selective uptake of HDL-cholesterol via promoting SR-BI expression and the activation of the PPARγ / LXRα pathway. Food Funct. 2018; 9(1): 624-635. doi: 10.1039/c7fo01107e

27. Sun L, Li E, Wang F, Wang T, Qin Z, Niu S, et al. Quercetin increases macrophage cholesterol efflux to inhibit foam cell formation through activating PPARγ-ABCA1 pathway. Int J Clin Exp Pathol. 2015; 8(9): 10854-10860.

28. Zou J, Feng D. Lycopene reduces cholesterol absorption through the downregulation of Niemann-Pick C1-like 1 in Caco-2 cells. Mol Nutr Food Res. 2015; 59(11): 2225-2230. doi: 10.1002/mnfr.201500221

29. Francisco V, Figueirinha A, Costa G, Liberal J, Ferreira I, Lopes MC, et al. The flavone luteolin inhibits liver X receptor activation. J Nat Prod. 2016; 79(5): 1423-1428. doi: 10.1021/acs.jnatprod.6b00146

30. Lin Y, Vermeer MA, Trautwein EA. Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters. Evid Based Complement Alternat Med. 2011; 2011: 801272. doi: 10.1093/ecam/nep007